Bioretec Oy
OMXH:BRETEC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.82
2.94
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bioretec Oy
Total Receivables
Bioretec Oy
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioretec Oy
OMXH:BRETEC
|
Total Receivables
€1.5m
|
CAGR 3-Years
72%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
R
|
Revenio Group Oyj
OMXH:REG1V
|
Total Receivables
€14.2m
|
CAGR 3-Years
19%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
M
|
Modulight Oyj
OMXH:MODU
|
Total Receivables
€2.3m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
O
|
Optomed Oyj
OMXH:OPTOMED
|
Total Receivables
€2.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nexstim Oyj
OMXH:NXTMH
|
Total Receivables
€2.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
B
|
Biohit Oyj
OMXH:BIOBV
|
Total Receivables
€6.9m
|
CAGR 3-Years
70%
|
CAGR 5-Years
21%
|
CAGR 10-Years
24%
|
|
Bioretec Oy
Glance View
Bioretec Ltd. develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics. The company is headquartered in Tampere, Lansi-Suomen. The company went IPO on 2021-09-28. The firm operates as a developer, manufacturer and commercializer of innovative bioresorbable orthopedic implants and implant materials used for the treatment of bone and soft tissue injuries. Bioretec Oy’s existing Activa product portfolio consists of bioabsorbable biopolymer products that are alreadyavailable in the market for applications in pediatrics, trauma surgery as well as sports surgery. Bioretec Oy has one Germany-based subsidiary, BRI.Tech GmbH. The Company’s products are used all over the world.
See Also
What is Bioretec Oy's Total Receivables?
Total Receivables
1.5m
EUR
Based on the financial report for Dec 31, 2023, Bioretec Oy's Total Receivables amounts to 1.5m EUR.
What is Bioretec Oy's Total Receivables growth rate?
Total Receivables CAGR 5Y
26%
Over the last year, the Total Receivables growth was 209%. The average annual Total Receivables growth rates for Bioretec Oy have been 72% over the past three years , 26% over the past five years .
You don't have any saved screeners yet
